Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price fell 0.9% during trading on Friday . The stock traded as low as $33.22 and last traded at $34.07. 7,643,464 shares traded hands during trading, a decline of 41% from the average session volume of 13,064,865 shares. The stock had previously closed at $34.39.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. Truist Financial raised their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a report on Wednesday, February 26th. TD Cowen restated a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Bank of America reaffirmed an "underperform" rating and set a $21.00 price target on shares of Hims & Hers Health in a research report on Thursday. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Finally, Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and a consensus target price of $37.23.
Check Out Our Latest Analysis on HIMS
Hims & Hers Health Price Performance
The company's 50-day moving average price is $37.64 and its two-hundred day moving average price is $27.60. The company has a market capitalization of $7.79 billion, a P/E ratio of 79.13 and a beta of 1.37.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Hims & Hers Health news, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the transaction, the chief executive officer now owns 109,956 shares in the company, valued at $3,256,896.72. This represents a 41.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,062,011 shares of company stock valued at $36,892,724. Insiders own 17.71% of the company's stock.
Institutional Investors Weigh In On Hims & Hers Health
Large investors have recently added to or reduced their stakes in the stock. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
